BPIQ Blog

$XBI $135 -3% Covid Updates $MRNA +3% and $CTLT +1% expand collaboration. source Pipeline Updates $FGEN -31% Roxa update. source $TMDX...

$XBI $138.63 +1% Covid Updates $VIR -2% Pre-clin data for covid California variant. source $CYDY +20% Compassionate use patient improved...

$XBI $137.03 +1% Covid Updates $EBS -13% Ph 3 data. source $MRNA +1% updated label for storage and doses. source Pipeline Updates $SUPN...

$XBI $137.03 +1% Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit...

$XBI $135.65 +4% Pipeline Updates $BTAI -3% Ph 1b/2 data. source $AVXL +6% Interim DSMB recommendation to continue ph 2b/3 study. source...

$XBI $130.11 +1% Pipeline Updates $EQ +10% Ph 1b data. source $BSGM +6% Awarded US patent. source $IMAB +6% IND approved for solid...

$XBI $129.36 -3% Covid Updates $VIR -6% Ph 2 data combo w/ $GSK $LLY. source $GRTS +1% 1st patient dosed in ph 1 study. source $HGEN +60%...

$XBI $133.06 -2% Covid Updates $VIR -2% & $GSK +1% Submit emergency use authorization request to FDA for VIR-7831 for early treatment of...

$XBI $135.21 +3% Covid Updates $SRNE +2% Updated results from ph 1b study of COVI-MSC. source $AZN +2% AZD1222 analysis confirmed. source...

$XBI $131.42 -5% Pipeline Updates $AKBA -5% Approval of Riona for additional indication in Japan. source $RDUS +10% Updates for...

$XBI $138.54 -6% Covid Updates $OMER -1% Dosing of patients with narsoplimab for covid-19 started earlier this month. source $AZN -3%...

$XBI $147.12 +1% Covid Updates $MRNA +1% New supply agreement with Philippines for 7M doses of covid-19 vaccine. source $RDHL +2%...

$XBI $145.07 +3% Pipeline Updates $CLVS +45% Presented data from ARIEL4 study, a ph 3 study of Rubraca for patients with advanced,...

$XBI $140.49 -5% Pipeline Updates $GILD -1% & $NOVO -1% Expand clinical collaboration into NASH. source $CYTK -5% Secondary analysis of...

$XBI $147.53 +1% Pipeline Updates $SAGE +3% 12-month data from ongoing ph 3 SHORELINE study of 30 mg and interim data from 50 mg of...

$XBI $145.89 -2% 📉 Covid Updates $MRNA +9% Doses first patient in ph 2/3 study of covid vaccine in pediatric population. source Pipeline...

$XBI $148.22 +1% 📈 Covid Updates $IBRX +1% Presents interim safety data from ph 1 study of AAV hAd5 T-cell covid vaccine. The...

$XBI $146.51 -0.5% 📉 Covid Updates $NVAX +8% Announced results from ph 3 covid trial in UK and ph 2b trial in South Africa. see full...

$XBI $146.95 +4% 📈 Covid Updates $VIR +32% and $GSK Announced phase 3 results that VIR-7831 reduces hospitalizations and risk of death...

$XBI $141.48 +0.5% 📈 Covid Updates $MRNA -1% First patients dosed in phase 2 study evaluating COVID-19 booster vaccine candidate. source...